Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)

Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)

A suite of early-stage therapy development funding programs called Innovation Grants to Nurture Initial Translational Efforts (IGNITE) is meant to serve as a feeder program to later-stage therapy development programs such as the Blueprint Neurotherapeutics Network for Small Molecules (BPN) and the Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics).

IGNITE program applications will be reviewed within the NINDS Scientific Review Branch and not at the Center for Scientific Review (CSR).

Upcoming receipt dates for IGNITE Funding Opportunities are October 19, 2021 and February 22, 2022

Definitions for Key Terms

Application Support Library-IGNITE Example: Milestones


Comparison of IGNITE Programs

Use this chart to help you decide which program better suits your needs.

Grant Program Entry Criteria End Goal

PAR-21-124: Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)


Strong biological rationale and premise

Relevance for therapy development

Available test agent(s) or library

Testing funnel to triage candidates, a battery of assays and starting agents that are suitable for BPN and BPN-Biologics

PAR-21-123: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Translational rationale for the proposed model system or ex vivo system and evidence of value for future drug discovery/development

Translationally relevant animal models, ex vivo systems, testing paradigms, and endpoints

PAR-21-122: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) 

Novelty- significant improvement over existing therapies

Biological Rationale

Relevance for therapy development

Well-characterized early-stage agents that are suitable for BPN and BPN-Biologics

Common to all three funding opportunities:

Timeline: 3 years total for both the R61 and R33 phases, with no more than 2 years in either phase.

Budget: Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $499,000 in direct costs in any single year.


Resources and Tools